WAT
Waters Corporation
NYSE · Healthcare · Medical - Diagnostics & Research · US
$409.10
−1.08%Aug 21, 2026, 00:00 UTC
Robert L. Carpio III resigned as Senior Vice President of Waters Analytical Sciences Division, effective August 20, 2026.
Aug 15, 2026, 07:45 UTC
Assetmark Inc. reduced its stake in Waters Corporation by 56.5% during the second quarter, selling 5,449 shares and retaining 4,196 shares, as disclosed in its 13F filing.
Source:Aug 4, 2026, 10:00 UTC
Waters Corporation reported second quarter 2026 financial results with total revenue of $1.645 billion, surpassing the high end of guidance, and organic revenue growth of 7% as reported and 9% in constant currency.
Jul 27, 2026, 12:10 UTC
Waters launches the Xevo TQ Absolute XR IVD Mass Spectrometer, a clinical IVD system with industry-leading sensitivity for applications in women's health, cancer assessment, and toxicology.
Jun 24, 2026, 12:00 UTC
IMU Biosciences and Waters Corporation announced a strategic partnership to accelerate development of IMU's AI-powered HD Immunology platform.
Source:Jun 8, 2026, 12:00 UTC
Waters launched industry-first reversed-phase bioseparation columns for faster GLP-1 characterization and LNP component analysis.
Source:Jun 3, 2026, 12:00 UTC
The FDA granted 510(k) clearance for the BD BACTEC FXI Culture System, a bloodstream infection diagnostic device.
Source: